EW
Edwards Lifesciences
Data as of 2026-10-14
Company attributes
Price
Interactive 5-year price history chart for EW. Latest close $86.39.
Pillar breakdown
0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)
- QualityProfit margins & asset efficiency56StrongHealth Care median (n=163) 51
- ValuePrice vs fundamentals22PoorHealth Care median (n=163) 52
- GrowthRevenue & earnings trajectory36WeakHealth Care median (n=163) 50
- MomentumRecent price strength54AverageHealth Care median (n=163) 66
- HealthBalance sheet & solvency82ExceptionalHealth Care median (n=163) 56
- ProfitabilityROE, ROA, ROIC69StrongHealth Care median (n=163) 49
- TechnicalTrend & volatility signals46AverageHealth Care median (n=163) 57
- RiskVolatility & drawdown profile56StrongHealth Care median (n=163) 47
Pillars not shown: Sentiment, ML (Phase 5+).
Fair price check
6 different valuation methods each estimate what EW should be worth, then we compare to today's price.
- EV/EBITDAOvervaluedthinks it's expensive — estimates $55.39, about 36% below today
- P/B multiplesOvervaluedthinks it's expensive — estimates $54.57, about 37% below today
- P/E multiplesOvervaluedthinks it's expensive — estimates $47.57, about 45% below today
- Graham (defensive)Overvaluedthinks it's expensive — estimates $32.44, about 62% below today
- DCF (2-stage)Overvaluedthinks it's expensive — estimates $25.84, about 70% below today
- Residual IncomeOvervaluedthinks it's expensive — estimates $22.86, about 74% below today
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
- Median fair
- $40.00
- Margin of safety(vs fair value)
- < −99%
- Max (ex-outliers)
- $55.39
- Tangible BVPS
- $12.64
Median of all applicable methods (current price $86.39). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.
Supporting dataRaw fundamentals & data-quality provenance behind the scores above
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $49.80B |
| Revenue (TTM) | $6.51B |
| Net income (TTM) | $1.00B |
| Operating cash flow (TTM) | $1.72B |
| CapEx (TTM) | $286.70M |
| Free cash flow (TTM)CFO − CapEx | $1.43B |
| Total assets | $13.87B |
| Total liabilities | $3.14B |
| Stockholders' equity | $10.62B |
| Cash & equivalents | $2.91B |
| Shares outstanding | 576.40M |
| EPS (basic) | $1.74 |
| EPS (diluted) | $1.74 |
| P/E ratio (TTM) | 49.55 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-08-04
- Latest period end
- 2026-07-31
- Filing lag
- 71 days
- Missing metrics
- 2(interest_expense, dividends_paid)
Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.